Although KRAS G12C inhibitors have shown promising activity in lung adenocarcinomas harbouring KRAS G12C , acquired resistance to these therapies eventually occurs in most patients. Re-expression of KRAS is thought to be one of the main causes of acquired resistance. However, the mechanism throug…